Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Aug 30 · below the Ichimoku cloud · RSI 35 · MACD below its signal · 1% above its 52-week low
None of the 29 investors followed here reported a position in 3933.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 3933.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 7, 2026 | Tsoi (Hoi Shan)Chairman of the Board | — | 24.65M | — |
| Jun 29, 2026 | Fang (Yuping)Former | — | 124.6K | — |
| Nov 12, 2025 | Choy (Siu Chit)Director (Executive) | — | 89.6K | — |
| Nov 12, 2025 | Fang (Yuping)Director (Executive) | — | 62.3K | — |
| Nov 12, 2025 | Leung (Wing Hon)Chief Financial Officer | — | 133.7K | — |
| Nov 12, 2025 | Tsoi (Hoi Shan)Chairman of the Board | — | 191.7K | — |
| Nov 12, 2025 | Zhu (Su Yan)Director (Executive) | — | 62.3K | — |
| Nov 12, 2025 | Zou (Xian Hong)Vice President | — | 62.3K | — |
| Jul 24, 2025 | Zou (Xian Hong)Vice President | Sale at price 2.02 per share. | 50K | $100.92K |
| Jul 20, 2025 | Zou (Xian Hong)Vice President | Sale at price 1.92 per share. | 150K | $288.69K |
| Nov 12, 2024 | Leung (Wing Hon)Chief Financial Officer | — | 133.7K | — |
| Nov 12, 2024 | Tsoi (Hoi Shan)Chairman of the Board | — | 191.7K | — |
| Nov 12, 2024 | Zhu (Su Yan)Director (Executive) | — | 62.3K | — |
| Nov 12, 2024 | Zou (Xian Hong)Vice President | — | 62.3K | — |
| Nov 12, 2024 | Choy (Siu Chit)Director (Executive) | — | 89.6K | — |
| Nov 12, 2024 | Fang (Yuping)Director (Executive) | — | 62.3K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.9 | 9.2 | -26.1 | -2.4 | -6.2 | -4.2 | 5.8 | -7.6 | -3.3 | -8.2 | −36.7% | ||
| 2025 | -6.8 | 13.5 | 11.3 | -4.9 | 5.2 | 2.7 | -1.6 | 3.8 | -2.1 | -16.3 | 1.6 | -9.5 | −6.9% |
| 2024 | -3.7 | 25.9 | 5.4 | 3.0 | -2.5 | -8.4 | 9.2 | -0.8 | 13.1 | 4.6 | 0.2 | 17.4 | +77.2% |
| 2023 | 5.9 | -9.4 | 16.2 | 16.1 | 8.8 | -5.2 | -4.7 | 12.5 | 13.1 | 0.8 | 0.1 | -12.4 | +43.1% |
| 2022 | 2.1 | -2.9 | -4.6 | -6.1 | -3.1 | 24.0 | -11.0 | -8.0 | -14.2 | 0.6 | 23.7 | 20.4 | +12.4% |
| 2021 | -2.2 | 4.6 | 1.8 | 10.8 | 14.0 | -12.1 | -14.4 | -3.7 | -1.3 | -4.8 | -9.5 | -2.2 | −20.9% |
| 2020 | -9.7 | 1.4 | 20.2 | 7.8 | 2.4 | -2.9 | 7.8 | 26.2 | -12.4 | -16.8 | -12.5 | -5.2 | −3.0% |
| 2019 | 7.0 | 7.0 | -2.5 | -1.1 | -3.5 | -5.4 | 3.1 | 4.2 | -8.4 | 9.5 | 6.4 | 18.3 | +36.5% |
| 2018 | 7.9 | 18.2 | 0.4 | 4.9 | 6.9 | -10.4 | -8.4 | -5.1 | -2.3 | -21.5 | -3.1 | -21.2 | −34.5% |
| 2017 | -8.1 | 3.1 | 1.4 | -3.7 | 6.4 | -0.8 | -4.9 | 24.3 | -4.4 | 16.7 | -7.2 | 0.8 | +20.3% |
| 2016 | -31.9 | -3.1 | 10.2 | 3.8 | -1.9 | -4.1 | -0.7 | 15.5 | 28.6 | -4.7 | -2.1 | 25.7 | +23.1% |
| 2015 | -15.5 | -7.3 | 2.3 | 44.4 | 13.9 | -6.0 | -16.6 | -17.1 | 1.5 | 5.1 | 3.9 | -0.2 | −5.3% |
| 2014 | 43.4 | 7.8 | -3.7 | 8.0 | -4.0 | 10.4 | -2.6 | 15.5 | -1.8 | 1.7 | -11.9 | -13.5 | +45.7% |
| 2013 | -4.3 | 5.9 | -8.2 | -15.7 | 1.0 | -5.8 | 7.9 | -7.4 | 1.1 | 16.8 | -2.8 | -2.2 | −16.2% |
| 2012 | 9.6 | 14.1 | -30.9 | -11.6 | 9.6 | -6.4 | 15.0 | 2.7 | -1.8 | 11.3 | -7.5 | -3.1 | −9.5% |
| 2011 | -21.7 | -3.5 | 16.1 | -6.6 | -3.5 | -9.0 | -30.1 | -7.5 | -19.3 | 1.7 | -29.2 | 3.7 | −72.0% |
| 2010 | -7.1 | 15.1 | 48.8 | 34.3 | 2.6 | 16.1 | 12.5 | 24.8 | 0.4 | -2.4 | 8.8 | -0.3 | +280.0% |
| 2009 | -11.7 | 38.7 | 10.4 | 11.2 | 6.5 | -6.4 | 0.3 | -5.8 | 1.7 | 20.7 | 6.5 | 10.8 | +104.9% |
| 2008 | -22.0 | 5.0 | -20.8 | 50.0 | 2.9 | 4.8 | 3.9 | -22.6 | -35.6 | -27.9 | 3.3 | 9.6 | −55.7% |
| 2007 | 41.2 | -4.1 | 22.8 | 2.6 | -12.2 | -11.0 | +33.4% |
The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers amoxicillin products; insulin series, antibiotics, and ophthalmic products; and veterinary drugs. It also provides 6-aminopenicillanic acid and penicillin G potassium products. In addition, the company provides endocrine and metabolism, anti-infection, and other human-used finished products, including ophthalmic drugs, topical dermatological drugs, etc.; and health and wellness products, such as general dietary supplements, healthcare food products, cross-border nutritional supplements, and medical and aesthetic skincare products for various categories comprising bone and joint nutrition, intestinal regulation, cardiovascular health, vision protection, and immunity enhancement. Further, it is involved in the research and development, production, sale, and technical services of economic and companion animal medicines for livestock, poultry, and aquatic products and pets. The company has operations in the People's Republic of China, India, Europe, the Middle East, South America, rest of Asian regions, and internationally. The United Laboratories International Holdings Limited was founded in 1990 and is headquartered in Yuen Long, Hong Kong.
Buy / hold / sell counts
No recent headlines.